Stay updated on Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the Phase 1 safety study of the antibody-drug conjugate XMT-1536 (upifitamab rilsodotin) administered in combination with Carboplatin for participants with high-grade serous ovarian cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:24.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing more detailed examples and general information about clinical research. The new description includes specific inclusion criteria for participants, such as age, gender, and health conditions.
    Difference
    35%
    Check dated 2024-05-22T21:03:16.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:49:19.000Z thumbnail image

Stay in the know with updates to Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Upifitamab Rilsodotin+Carboplatin in Ovarian Cancer Clinical Trial page.